ATM Is Required for the Prolactin-Induced HSP90-Mediated Increase in Cellular Viability and Clonogenic Growth After

Ödül Karayazi Atici1,2, Anna Urbanska1,2, Sesha Gopal Gopinathan1,2

  • 1Department of Biological Sciences, University of Calgary, Calgary, Alberta, Canada.

Endocrinology
|November 30, 2017
PubMed

Insights

Prolactin (PRL) enhances breast cancer cell survival against DNA damage via the JAK2-STAT5-HSP90 pathway. ATM kinase is crucial, and inhibiting HSP90 or ATM synergizes with chemotherapy.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Cell Signaling

Background:

  • Prolactin (PRL) is a survival factor for breast cancer cells.
  • The precise PRL signaling pathway and its mechanism remain largely unknown.
  • Heat shock protein 90 (HSP90) alpha was previously identified as a target gene in the PRL-Janus kinase 2 (JAK2)-signal transducer and activator of transcription 5 (STAT5) pathway.

Purpose of the Study:

  • To investigate the role of HSP90 in PRL-mediated cell viability in response to DNA damage.
  • To elucidate the involvement of the ataxia-telangiectasia mutated (ATM) kinase in this process.
  • To explore potential therapeutic strategies by targeting this pathway.

Main Methods:

  • Utilized breast cancer cell lines treated with DNA-damaging agents (doxorubicin, etoposide).
  • Employed PRL receptor antagonist, HSP90 inhibitors (17-allylamino-17-demethoxygeldanamycin, BIIB021), JAK2 inhibitor (G6), and ATM inhibitor (KU55933).
  • Assessed cell viability, protein levels (JAK2, ATM, p-ATM), and used short interfering RNA (siRNA) against ATM in various culture models.

Main Results:

  • PRL significantly increased breast cancer cell viability following DNA damage, an effect blocked by a PRL receptor antagonist.
  • HSP90 inhibitors reduced PRL-mediated viability and decreased levels of JAK2, ATM, and phosphorylated ATM.
  • Inhibitors of JAK2 and ATM, as well as ATM siRNA, abolished PRL-induced cell survival, confirming pathway involvement and crosstalk.
  • Drug synergism was observed between ATM/HSP90 inhibitors and doxorubicin.

Conclusions:

  • ATM plays a critical role in the PRL-JAK2-STAT5-HSP90 pathway.
  • This pathway mediates cellular resistance to DNA-damaging agents in breast cancer.
  • Targeting HSP90 or ATM may enhance the efficacy of chemotherapy against breast cancer.

Related Concept Videos

DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
10.2K
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
3.2K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
8.7K